Anti-diabetic Effects of Persimmon Leaf Extract
Primary Purpose
Prediabetes
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Persimmon leaf extract
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Prediabetes focused on measuring prediabetes, blood glucose, clinical trial
Eligibility Criteria
Inclusion Criteria:
- Age 20-75 years
- Fasting blood glucose (FPG) 100~140 mg/dL or postprandial blood glucose (PPG) 140~250 mg/dL
Exclusion Criteria:
- FPG more than 140 mg/dL
- 2h PPG more than 200 mg/dL
- Type 1 diabetes or HbA1c more than 9.0%
- treatment with corticosteroids within the past 4 weeks
- cardiovascular disease
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Treatment sequence 1
Treatment sequence 2
Arm Description
PLE (persimmon leaf extract) once a day during 8 weeks cross-over to placebo once a day during 8 weeks.
Placebo once a day during 8 weeks cross-over to PLE once a day during 8 weeks.
Outcomes
Primary Outcome Measures
Fasting and postprandial plasma glucose
Secondary Outcome Measures
Fasting plasma insulin
C-peptide
Glycated hemoglobin (HbA1c)
adiponectin
leptin
resistin
Markers of Inflammation
Tumor necrosis factor alpha (TNF-α)
Interleukin-6 (IL-6)
Monocyte chemoattractant protein-1 (MCP-1)
Full Information
NCT ID
NCT02706821
First Posted
March 8, 2016
Last Updated
March 13, 2016
Sponsor
Chonbuk National University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02706821
Brief Title
Anti-diabetic Effects of Persimmon Leaf Extract
Official Title
An Eight-week, Randomized, Double-blind, Placebo-controlled Crossover Clinical Trial of Persimmon Leaf Extract on Anti-diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
March 2016
Overall Recruitment Status
Completed
Study Start Date
February 2014 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
February 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chonbuk National University Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The investigators performed a 8-week, randomized, double-blind, placebo-controlled crossover human trial to evaluate the efficacy and safety of persimmon leaf extract on blood glucose. The investigators measures changes in diabetes associated parameters, including fasting blood glucose, postprandial blood glucose, insulin, C-peptide and HbA1c.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prediabetes
Keywords
prediabetes, blood glucose, clinical trial
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
34 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Treatment sequence 1
Arm Type
Active Comparator
Arm Description
PLE (persimmon leaf extract) once a day during 8 weeks cross-over to placebo once a day during 8 weeks.
Arm Title
Treatment sequence 2
Arm Type
Active Comparator
Arm Description
Placebo once a day during 8 weeks cross-over to PLE once a day during 8 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Persimmon leaf extract
Intervention Description
Persimmon leaf extract (PLE), crossover design
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Placebo, crossover design
Primary Outcome Measure Information:
Title
Fasting and postprandial plasma glucose
Time Frame
baseline day 57, 85 and 141
Secondary Outcome Measure Information:
Title
Fasting plasma insulin
Time Frame
baseline and day 57, 85 and 141
Title
C-peptide
Time Frame
baseline and day 57, 85 and 141
Title
Glycated hemoglobin (HbA1c)
Time Frame
baseline and day 57, 85 and 141
Title
adiponectin
Time Frame
baseline and day 57, 85 and 141
Title
leptin
Time Frame
baseline and day 57, 85 and 141
Title
resistin
Time Frame
baseline and day 57, 85 and 141
Title
Markers of Inflammation
Time Frame
baseline and day 57, 85 and 141
Title
Tumor necrosis factor alpha (TNF-α)
Time Frame
baseline and day 57, 85 and 141
Title
Interleukin-6 (IL-6)
Time Frame
baseline and day 57, 85 and 141
Title
Monocyte chemoattractant protein-1 (MCP-1)
Time Frame
baseline and day 57, 85 and 141
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age 20-75 years
Fasting blood glucose (FPG) 100~140 mg/dL or postprandial blood glucose (PPG) 140~250 mg/dL
Exclusion Criteria:
FPG more than 140 mg/dL
2h PPG more than 200 mg/dL
Type 1 diabetes or HbA1c more than 9.0%
treatment with corticosteroids within the past 4 weeks
cardiovascular disease
12. IPD Sharing Statement
Learn more about this trial
Anti-diabetic Effects of Persimmon Leaf Extract
We'll reach out to this number within 24 hrs